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Abstract 
In bipolar disorders, there are unclear diagnostic boundaries with unipolar depression and 
schizophrenia, inconsistency of treatment guidelines, relatively long trial-and-error phases of 
treatment optimization, and increasing use of complex combination therapies lacking empirical 
evidence. These suggest that the current definition of bipolar disorders based on clinical symptoms 
reflects a clinically and etiologically heterogeneous entity. Stratification of treatments for bipolar 
disorders based on biomarkers and improved clinical markers are greatly needed to increase the 
efficacy of currently available treatments and improve the chances of developing novel therapeutic 
approaches. This review provides a theoretical framework to identify biomarkers and summarizes 
the most promising markers for stratification regarding beneficial and adverse treatment effects. 
State and stage specifiers, neuropsychological tests, neuroimaging, and genetic and epigenetic 
biomarkers will be discussed with respect to their ability to predict the response to specific 
pharmacological and psychosocial psychotherapies for bipolar disorders. To date, the most reliable 
markers are derived from psychopathology and history-taking, while no biomarker has been found 
that reliably predicts individual treatment responses. This review underlines both the importance of 
clinical diagnostic skills and the need for biological research to identify markers that will allow the 
targeting of treatment specifically to sub-populations of bipolar patients who are more likely to 
benefit from a specific treatment and less likely to develop adverse reactions. 
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Psychiatric research goes to great lengths to develop tests that can predict specific therapeutic 
successes (Frey et al., 2013). Such tests allow for adjustment of therapies to pathological processes 
and are of clinical relevance if the estimation of therapeutic success based on conventional 
diagnostic methods is imprecise. More specifically, stratified medicine intends to bring into line 
diagnosis, therapy, and prevention with the genetic predisposition of patients. In the case of bipolar 
disorders, no risk genes and no genes associated with treatment success have been reliably 
identified. In this review, the term “stratified medicine” has been broadened to include all kinds of 
predictors of therapy success. At the end of the article, we focus on the potential of genetic and 
epigenetic markers in bipolar disorders. 
 
Why stratifying treatments for bipolar disorders?  
There is much evidence that conventional diagnosis of bipolar disorders is imprecise (Angst, 2004, 
2008; Angst et al., 2010; Simpson et al., 2002; Zimmermann et al., 2009). While international 
treatment guidelines of frequent psychiatric disorders, such as major depression or schizophrenia, 
are relatively consistent, the guidelines for bipolar disorders are strikingly inconsistent and 
heterogeneous (Nivoli et al., 2011) . This is particularly the case for bipolar depression in which 
considerable differences between recently published national and international treatment guidelines 
exist (Samalin et al., 2013). Despite the large number of clinical studies on bipolar depression, 
fundamental questions remain unclear. Thus, there is no consistent approach regarding whether 
bipolar depression should primarily be treated by a mono-therapy or combined therapy (Licht et al., 
2008). Evidence-based expert opinions diverge considerably regarding the role of lithium and 
lamotrigine (Calabrese et al., 2008; Geddes et al., 2009). Additionally, the application of 
antidepressants is unclear (Pacchiarotti et al., 2013) . Even quetiapine, with relatively consistent 
evidence of efficacy, is not recommended as a first-line treatment in all guidelines. Further evidence 
for the urgent need of better diagnosis are the relatively low mean response rates of antidepressant 
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(McElroy et al., 2010), anti-manic (Cipriani et al., 2011) and mood-stabilizing treatments in bipolar 
disorders; insufficient prediction of adverse drug reaction; long trial-and-error phases of treatment 
adjustment; and increasing use of complex combination therapies without solid evidence. 
 
Stratification based on psychopathological characteristics  
The American Psychiatric Association’s third edition of the Diagnostic and Statistical Manual (DSM-III, 
1980) aimed to operationalize clinical psychiatric diagnosis. This was required in order to study 
scientific diagnosis and markers regarding prediction of treatment success. A group of experts 
defined clusters of symptom patterns for courses as diagnostic criteria based on their clinical 
experience. In this way, defined diagnoses have been validated by epidemiological methods. 
Validation was mainly based on the criteria of Robins und Guze (Robins and Guze, 1970); the 
predictive efficiency and stability of diagnosis were evaluated by longitudinal studies and consistency 
of risk factors have been examined in family studies. As genetic risk factors in severe psychiatric 
diseases, such as schizophrenia and bipolar disorder, are of great importance, family studies became 
the most important method for validation of diagnostic criteria. The concept of bipolar disorder owes 
its success to family studies simultaneously conducted and published by Jules Angst und Carlo Perris 
(Angst and Perris, 1968). Those studies demonstrated an increased risk for bipolar disorder in 
relatives of bipolar patients, whereas the risk in relatives of patients suffering from major depression 
was not increased.  
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From a present-day perspective, subdivision of affective disorders into unipolar and bipolar subtypes 
has been a great success of psychiatric epidemiology because these subtypes are not only distinct 
with regard to etiology and clinical course, but also in terms of responding to pharmacologic 
treatment. In particular, the specific relapse prevention with lithium impressionably demonstrates 
the benefit of this diagnostic concept (Geddes et al., 2004). 
In recent years, clinical research has identified psychopathologic markers in patients with bipolar 
disorder that contribute to the prediction of treatment success. Those findings describe an important 
step towards stratified treatments. Thus, a typical manic-depressive course with full inter-episode 
remission predicts a good efficiency of lithium. Mixed manic-depressive forms respond relatively well 
to second-generation antipsychotics, such as olanzapine or asenapine (Grunze and Azorin, 2014; 
Kruger et al., 2005). Agitation in manic episodes is associated with good efficiency of loxapine, 
asenapine, and aripiprazole (Brown et al., 2013; Kwentus et al., 2012; McIntyre et al., 2009).  
Seasonal forms are positive predictors for a response to light therapy (Golden et al., 2005), while 
forms with predominant depressive episodes predict a good prophylactic effect of lamotrigine 
(Colom et al., 2006). Since lithium has a potent anti-suicidal effect and reduces suicide risk by 80% in 
individuals with affective disorders (Baldessarini et al., 2006), an increased suicidal risk is an 
important predictor for the use of lithium-treatment, irrespective of its mood-stabilizing effect. This 
stratified use of lithium corresponds relatively well with the goal of stratified medicine to adjust 
therapies to disease processes. This is because we assume that lithium reduces the specific lethality 
of suicidal attempts by inhibition of aggressive impulses. 
Besides the aforementioned progresses in clinical practice, serious disadvantages and fundamental 
questions remained unanswered despite decades of intensive research. There are substantial 
problems with the concept of bipolar disorder: 1) Depressive disorders become apparent as bipolar 
disorders only over time as patients are not treated in an optimum manner for years; 2) Past manic 
episodes are poorly remembered, which leads to further misdiagnosis (Angst et al., 2005a); and 3) 
There is substantial uncertainty about where to draw the line between unipolar and bipolar affective 
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disorders. Jules Angst and others have convincingly proven that—based on epidemiologic criteria, 
such as family history, course, and comorbidity—up to 40% of patients with major depressive 
disorders diagnosed based on the DSM-IV criteria suffer from subsyndromal hypomania and should 
therefore be classified as bipolar spectrum disorder(Angst et al., 2011; Angst et al., 2010). As listed in 
Table 1, various clinical characteristics have been identified to predict bipolar spectrum disorders 
(Angst et al., 2005b; Dudek et al., 2013; Lapalme et al., 1997).  
However, there is evidence from placebo-controlled randomized clinical trials that subsyndromal 
manic states and maniform symptoms are less relevant for the choice of therapeutic approach than 
previously assumed. Thus, antidepressants in bipolar spectrum disorders might be as effective as 
they are in unipolar depression (Perlis et al., 2011), and with antidepressant-treated manic 
symptoms, they may not occur more often in spectrum disorders than without treatment. In 
contrast, other studies have reported the presence of subthreshold manic symptoms as a predictor 
of poor antidepressant response in bipolar depression (Pacchiarotti et al., 2011).  This controversy 
indicates that stratification based on the criteria of Robins and Guze may not necessarily contribute 
to stratification of treatment strategies (Robins and Guze, 1970). Only markers with predictive value 
in terms of therapeutic response have the potential to improve the therapeutic practice in a crucial 
way (Perlis, 2011). To this end, treatment studies with patients with bipolar II disorder and bipolar 
spectrum disorders are of high clinical relevance. Overall limits are set to personalize treatment 
based on psychopathologic characteristics because many clinical symptoms are unspecific and allow 
no inferences about the underlying disease processes.  
 
Stratification based on endophenotypic markers  
The concept of endophenotypes  
Gottesman and Shields (Gottesman and Shields, 1973) recognized early a fundamental problem of 
psychiatric genetics. Psychiatric conditions, as defined in the DSM and other established diagnostic 
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manuals, do not represent adequate phenotypes for research since they are conceptualized as 
syndromes and are not related to mechanisms of illness. Furthermore, they assumed a long pathway 
from genes to clinical symptoms, which is difficult to reveal because of complex gene-by-gene 
interactions and gene-by-environment interactions over time. Despite intensive and expensive 
research, no risk genes for strong hereditable psychiatric diseases like bipolar disorders and 
schizophrenia have been reliably identified. This seems to acknowledge that they were right (Sullivan 
et al., 2012). In theoretical articles, they suggested vanquishing this methodical weakness of 
psychiatric genetics through the implementation of endophenotypes.  
Endophenotypes are intermediate phenotypes standing between genes and gene products on the 
one hand and clinical syndromes on the other hand. The concept of endophenotypes assumes that 
there are fewer genes and less complex gene-environment interactions involved in the variation of 
endophenotypes than in psychological syndromes (Glahn et al., 2014; Gottesman and Gould, 2003). 
Thus, it seems useful to identify genetic factors underlying endophenotypes in the first step and 
associate the biological consequences of the identified gene variants with clinical symptoms 
afterwards. Endophenotypes can be categorized according a gradient between genes and clinical 
symptoms: for example, neuropsychological endophenotypes are located nearer to the symptoms 
whereas concentrations of neurotransmitters measured by magnetic resonance spectroscopy (MRS) 
lie nearer to the genetic pole of the gradient. In other words, the endophenotype approach assumes 
that genetic underpinnings of molecular biological measures is less complex than those of complex 
behaviors irrespective of the heritability of the phenotype’s total genetic risk. (Hasler et al., 2006).  
The validation criteria for endophenotypes involve the relationship with psychiatric disorders, 
heredity, independence from changing clinical symptomatology, and increased occurrence in healthy 
relatives (Hasler et al., 2006; Hasler et al., 2004). The later criterion ensures an association between 
the genetic risk factors of the endophenotype and those of illness (Hasler and Northoff, 2011). 
Endophenotypes are not diagnostic markers in a traditional sense (i.e., specificity and sensitivity of a 
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specific psychiatric disorder are not validation criteria). In the context of stratified medicine 
(Schumann et al., 2014), it is to be expected that endophenotypes that are related to both risk genes 
and clinical symptoms can help to tailor psychiatric diagnostic, therapy, and prevention to 
pathological processes.  
 
Neuropsychology 
In schizophrenia, measures of general cognitive performance meet the validation criteria of 
endophenotypes (Snitz et al., 2006; Yeo et al., 2014). An advantage of such simple 
neuropsychological endophenotypes is that they can be effortlessly assessed in studies with large 
samples as well as in clinical daily routines. 
Its disadvantage is that they exist near the symptom-pole on a symptom-genotype-gradient. In the 
case of bipolar disorder, there is an additional disadvantage that studies on neuropsychological 
deficits in bipolar patients and their healthy relatives revealed contradictory results (Bora et al., 
2009). Common cognitive deficits appear to not be a risk factor of bipolar disorder. In fact, there is 
evidence that an above-average intelligence quotient during adolescence is a risk for the later 
occurrence of a bipolar disorder (MacCabe et al., 2010). Deficits in verbal learning and verbal 
memory meet the criteria of endophenotypes best (Balanza-Martinez et al., 2008; Hasler et al., 
2006), followed by attention deficits and disturbance executive functions like response inhibition 
(Bora et al., 2009).  
Loss of interests, reduced reaction upon positive events, and lack of motivation are core symptoms 
of bipolar depression, whereas uncontrollable excitation and increased motivation are core 
symptoms of mania. These symptoms point to dysregulation of the reward system, which is 
determinative of the regulation of motivation and drive. Relatively simple behavioral experiments, 
such as the monetary incentive delay task are proper for quantifying the disturbance of this system in 
affective disorders (Hasler et al., 2009; Knutson et al., 2008; Pizzagalli et al., 2009; Stoy et al., 2012). 
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Since such measures are dependent on current affective symptoms, they might not qualify for 
endophenotypes. The validity of such measures in terms of the underlying pathological processes in 
affective disorders can be improved by combining them with pharmacological manipulation. As 
dopamine plays a central role in the brain reward system, substances enhancing or inhibiting 
dopamine neurotransmission are often used (Hasler et al., 2006; Hasler et al., 2009). This approach is 
comparable with the glucose intolerance test, which is more convincing in the diagnosis of diabetes 
mellitus than simple measures of the fasting plasma glucose concentration. Nevertheless, the utility 
of such combined measures in research and practice are considerably limited by their complexity and 
costs. 
 
Neuroeconomics 
A new, important contribution derives from behavioral economics. The economic decision theory 
assumes that options of action are represented in the brain(Glimcher and Rustichini, 2004). The brain 
reward system assigns a value to each of these options (Schultz, 2006). The option of action with the 
greatest value will be selected and executed. Finally, the reward system evaluates the outcome, 
which determines future representation and evaluation processes. Extensions of this theory regard 
the influence of uncertainty, and temporal and social factors on decision making. Neuroeconomic 
research has convincingly proven that decision theory qualifies for investigation the neurobiology of 
the human motivation (Rangel et al., 2008). Since motivation disorders are a central feature of 
affective disorders, neuroeconomics has the potential to revolutionize psychiatric research (Hasler, 
2012). Chandler and co-workers showed by means of behavioral experiments based on the theory of 
expected utility that persons with bipolar disorder exhibit a complex dysregulation of risk-evaluation 
which facilitates the alternations of depressive and manic phases (Chandler et al., 2009). Future 
research will show if such experiments are suitable to uncover pathological processes in affective 
disorders, which would be an important step toward stratified treatment.  
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Functional imaging 
Current imaging methods allow the measuring of functional, structural, and chemical changes in 
patients with bipolar disorders. The considerable differences of these applied methods, commonly 
small samples, and rather low consistency of the findings complicate the possibility to describe 
precisely the pathological processes in bipolar or other disorders in terms of the dysfunctional brain 
region and neural networks.  
The findings of functional imaging studies are particularly heterogeneous and therefore difficult to 
interpret with regard to applicability as endophenotypes (Keener and Phillips, 2007; Vargas et al., 
2013). In addition, the use of psychological experiments, which differ from study to study, contribute 
to heterogeneity. A relatively well-examined paradigm in affective disorders is the measurement of 
neural reactions to emotional facial expressions. This paradigm has demonstrated a relatively 
consistent increased neural activity of subcortical, limbic brain regions (amygdala, parahippocampal 
formations, striatum) in combination with reduced activity of the lateral prefrontal cortex 
(Delvecchio et al., 2012). This pattern of findings is not specific for bipolar disorders but corresponds 
to the main finding of functional imaging studies of a broad spectrum of mood and anxiety disorders, 
including unipolar depression and anxiety disorder. Those findings will not be relevant for stratified 
medicine until it can be shown that they can be linked with therapy (e.g., if patients with strong 
increased subcortical activity respond better to a certain antidepressant treatment than persons 
without an increased activity). Antidepressants seem to be particularly efficacious in mood disorder 
patients with limbic hyperactivity (Chen et al., 2007; Mayberg et al., 1997). Additionally, deep brain 
stimulation seems to be particularly efficacious in patients with limbic hyperactivity that was 
normalized by stimulation (Mayberg et al., 2005). This is of special interest in the context of this 
review because Mayberg and colleagues recently found that deep brain stimulation is efficacious not 
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only in unipolar but also in bipolar depression without provoking manic or hypomanic symptoms 
(Holtzheimer et al., 2012). 
 
Structural imaging 
Structural imaging studies in bipolar disorders yielded four main findings: 1) Abnormal brain volume 
of the anterior cingulate and a decreased integrity of white matter are associated with the genetic 
risk for bipolar disorders (McDonald et al., 2004; Whalley et al., 2013); 2) During the course of bipolar 
disorder, the regional brain volume decreases (Lim et al., 2013); and 3) Lithium-treated bipolar 
patients exhibit larger brain volumes on average than those who are not treated with lithium 
(Hallahan et al., 2011). 4) The frequency of white matter atrophic alterations are higher in bipolar 
disorder patients than in age-matched controls (typically bright spots in T2-weighted MRI images, 
also referred to as white matter hyperintensities) (Ahn et al., 2004; Aylward et al., 1994; Beyer et al., 
2009; Marlinge et al., 2014). 
There is some evidence that excessive release of corticosteroids, glutamate neurotoxicity, 
mitochondrial dysfunction, and stress-induced decrease of neurotrophic factors lead to the decrease 
of gray matter (Munakata et al., 2005; Nugent et al., 2006; Snyder et al., 2011; Stork and Renshaw, 
2005). These neurotrophic and neurotoxic processes, which putatively contribute to an increased 
relapse risk in the course of illness, have important implications in terms of stratification of 
treatments. It seems natural that pathological processes differ not only between persons but also 
between stages of illness. A recent Task Force Report of the International Society for Bipolar 
Disorders concluded that staging models have the potential to improve treatment selection in bipolar 
disorders, and that the broadly defined categories of early and late stage are heuristically useful 
(Kapczinski et al., 2014).  Given the finding that response to an antidepressant correlates positively 
with gray matter volume of the anterior cingulate, insula, and right temporoparietal cortex (Chen et 
al., 2007), it is conceivable that antidepressants are basically efficacious in early stages of bipolar 
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disorder. Moreover, there is preliminary evidence of an increase in gray matter volume as a 
longitudinal effect of a lithium treatment (Moore et al., 2009). In the presence of structural brain 
alterations, neuroprotective drugs, such as lithium and valproic acid, might be the best treatment 
options since they may positively interact with neurotrophic processes potentially underlying the 
clinical symptoms (Chiu et al., 2013). This hypothesis can be tested by treatment studies using 
structural imaging at the onset and end of controlled treatments.  
Abnormalities in the sense of white matter hyperintensities are often observed in older patients after 
cerebrovascular insults as well as in patients with migraine. In bipolar disorders, such alterations 
typically emerge at an early age before or shortly after the onset of the disorder (Hasler et al., 2006). 
This indicates that impairments of neuroplasticity and cellular resilience, which potentially lead to 
neural atrophy and cell death, are important pathological processes in bipolar disorder (Fries et al., 
2014; Machado-Vieira et al., 2014). In accordance with this hypothesis is the observation that white 
matter hyperintensities predict a good response to treatment with lithium (Kato et al., 2000).  
 
Magnetic resonance spectroscopy 
MRS is a relatively new imaging method, which enables the measurement of the concentration of 
specific molecules. The most consistent MRS finding in bipolar disorder has been an increase in Glx in 
the prefrontal cortex (Gigante et al., 2012), namely in all examined prefrontal brain regions 
irrespective of medication. Glx reflects the total concentration of glutamate and glutamine. By 
interpreting this finding, one has to take into account that Glx is not a direct measurement of 
glutamatergic neurotransmission, because only 20% of glutamate in the brain serves as a 
neurotransmitter; 80% has a metabolic function. In this sense, bipolar disorder can be considered as 
a metabolic brain disorder. That blockade of mitochondrial metabolism leads to an increase of 
glutamate (Clausen et al., 2001) suggests that mitochondrial dysfunction plays a role in the 
pathogenesis of bipolar disorder (Stork and Renshaw, 2005). Mood stabilizing medications, such as 
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lithium, valproic acid, and lamotrigine, modulate the glutamate system; it would be important to 
know, in the sense of stratified medicine, whether or not there is a correlation between abnormal 
prefrontal Glx and efficacy of these medications. There is preliminary evidence for an association 
between low pretreatment glutamine levels and a good antidepressant efficacy of ketamine 
(Salvadore et al., 2012). As decreased Glx is relatively consistent, as per MRS findings in unipolar 
depression, Glx has the additional potential to enable a biological valid differentiation between 
unipolar and bipolar affective disorders (Hasler and Northoff, 2011). 
 
Immunology 
Compared with the general population and with humans with unipolar depression, bipolar patients’ 
risk of premature death is 1.5 to 3-fold increased, irrespective of the risk of suicide. The main reason 
for this excess mortality is thought to be the high comorbidity with somatic diseases: up to 80% of 
bipolar patients also suffer from metabolic and/or cardiovascular disease (Swartz and Fagiolini, 2012; 
Taylor and MacQueen, 2006). This high rate of somatic comorbidity cannot be explained only by 
unwanted side effects of pharmacotherapy or by unhealthy lifestyle; rather, it points to common 
pathogenetic processes. Based on immunological studies, it has been proposed that bipolar disorder 
be understood as a multisystem inflammatory disease (Leboyer et al., 2012). This hypothesis is based 
on the frequent observation of increased pro-inflammatory proteins, such as interleukin-6 and tumor 
necrosis factor alpha in both bipolar disorder and cardiovascular disease (Kunz et al., 2011). 
Interleukin-6 has appeared to be associated with illness progression and late stages of the disease 
(Grande et al., 2014). Therapies that act upon these immunologic processes will contribute to more 
targeted treatment in inflammation-associated bipolar disorders. Such treatments likely contribute 
to the reduction of excess morbidity and mortality in patients with bipolar disorder. 
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Stratified psychotherapy of bipolar disorders 
Apart from psychoeducation, many forms of psychotherapy in bipolar disorders have proven 
effective. Interpersonal and social rhythm therapy, cognitive behavioral therapy, and family-focused 
therapy increase the probability of recovery, decrease time to recovery, and improve interpersonal 
skills and life satisfaction (Miklowitz, 2006). Similarly, pharmacotherapy response rates are typically 
low to moderate and scientific criteria on the selection of specific types of psychotherapy related to 
individual characteristics and the state of the illness are still lacking (Reinares et al., 2014). This lack 
can lead to long trial-and-error phases and may considerably reduce the effectiveness of 
psychological treatments. Psychotherapy research has labeled the lack of significant differences 
among effect sizes of available psychotherapies as the “Dodo bird verdict,” referring to Carroll’s 
novel “Alice’s Adventures in Wonderland,” in which Dodo said: “Everybody has won, and all must 
have prizes.” However, this verdict is only correct at the group level and there is evidence that 
responses to distinct therapeutic methods and distinct therapists vary considerably across individual 
patients. Staging and illness awareness may be particularly relevant predictors of the response to 
psychosocial interventions. For example, patients with no insight and willingness to participate in 
such interventions may particularly benefit from family psychoeducation, rather than from patient-
focused interventions. 
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There are some promising leads that personality characteristics can predict responses to 
psychotherapy. For example, dependent personality traits may be a positive predictor of the 
response to highly structured behavioral therapy (Grawe, 2004). The state of an illness may be 
another important predictor of psychotherapy response. Data from controlled studies point to the 
finding that patients with only a few episodes benefit more from psychoeducation and 
psychotherapy than patients in late illness states (Reinares et al., 2014). In contrast, patients with 
chronic bipolar disorder may particularly benefit from psychological interventions that focus on 
specific functional impairments, such cognitive, interpersonal, and work-related deficits (Popovic et 
al., 2012; Torrent et al., 2013). Recent data suggest that functional remediation is not only effective 
in late stages of bipolar-I-disorder, but also of bipolar-II-disorder (Sole et al., 2014). 
Many psychotherapies include a “personalization“ of their interventions. For example, in behavioral 
activation, positive activities with antidepressant effects are systematically assessed, sometimes 
using extensive lists of potentially pleasurable activities. This kind of personalization of 
psychotherapies has great potential because it takes advantage of the fact that the response to 
behavioral change can usually be assessed easier and faster than the response to biological 
interventions. This potential should be used more systematically in the sense of stratified medicine. 
The interpersonal and social rhythm therapy has been invented with the intention of specifically 
acting upon a disturbance of the circadian rhythm (Frank et al., 2005; Frank et al., 2000). This 
disturbance is likely an important process of disease in bipolar patients. An indication for it is the 
occurrence of hypomanic symptoms after sleep deprivation (Hasler et al., 2006). The relatively well-
established biology and genetics of circadian rhythm will possibly contribute to the development of 
biomarkers that predict the response to treatments modifying the circadian rhythm.  
 
Adverse drug reactions 
 16 
Frequent problems with compliance and common somatic comorbidities in bipolar disorders means 
that drugs are not only chosen based on their effect but also based on their profile of adverse drug 
reactions (ADR). Stratification based on ADR profiles is relatively well advanced. The corrected QT 
interval derived from modern electrocardiogram machines is increasingly used to assess the threat of 
severe cardiac ADRs. This is particularly of great importance when drugs are combined since a drug-
prolonging QTc can potentiate in drug combination. Risk factors of the metabolic syndrome— 
such as abdominal fat distribution and increased serum triglyceride, HDL cholesterol, blood pressure, 
and fasting glucose—represent relative contraindications for atypical antipsychotics, which cause 
frequent metabolic ADRs. Polysomnography can help to assess the danger of respiratory depressive 
psychotropic drugs. The identification of subjects carrying the HLA-B*1502 allele and the avoidance 
of carbamazepine therapy in these subjects has been strongly associated with a decrease in the 
incidence of carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis 
(Chen et al., 2011). The success of this “stratification“ is considerable; despite increasing 
polypharmacy, the frequency of dangerous ADRs is decreasing (Greil et al., 2012). 
 
Genetics 
Genetic factors constitute approximately 90% of bipolar I disorder causes (Kieseppa et al., 2004; 
McGuffin et al., 2003). However, identification of individual risk genes is still unsuccessful. This is 
striking since risk genes have been found for complex genetic diseases with lower heritability than 
bipolar disorder, such as diabetes mellitus, Alzheimer’s disease, and breast cancer (Hasler et al., 
2006). 
As mentioned above, a major problem of psychiatric genetics is the fact that psychiatric disorders are 
defined as syndromal rather than based on pathologic processes. In this case, diverse pathological 
processes leading to the clinical image of bipolar disorder identification of risk genes of bipolar 
disorder as a symptom-based, defined phenotype is complicated or impossible (Kendler, 2006). 
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Another problem is the assessment of genetic variance. Even genome-wide association studies assess 
only a section of a possible variance; namely, the commonly occurring single nucleotide 
polymorphisms (SNPs). If, for example, very rare or spontaneous polymorphisms play an important 
role in the pathogenesis of bipolar disorders, they would not be detected by current methods 
(Kerner, 2014). 
Recent new mathematical methods enable the computation of the amount of risk of illness 
contingent on SNPs, which are usually determined by GWAS studies (Kendler, 2013). A corresponding 
study showed that a 41% risk for bipolar I disorder is defined by the GWAS data of Wellcome Trust 
Case Control Consortium (Lee et al., 2011). This is considerably more than in schizophrenia (14–24%) 
or somatic diseases, such as Crohn’s disease (24%) and diabetes mellitus type 1 (31%). This suggests 
that there is no fundamental hurdle regarding the way to the itemization of the genetics of bipolar 
disorders. Presumably, many genetic factors contribute to the risk of disease, each with a small 
effect. Such effects can be proven only in very large samples. 
In bipolar disorders, the risk gene candidates with the best evidence are CACNA1C and ANK3 
(Craddock and Sklar, 2013; Muhleisen et al., 2014). Both genes code for proteins regulate, as part of 
the ion channels, the neuronal excitability. These findings suggest that ion channels are decisive in 
the pathogenesis of bipolar disorders and drugs that act on ion channels may have therapeutic 
effects. 
Regarding stratification of currently available therapies, genetic markers are crucial to predict 
treatment success. Thus far, identification of such markers has not been successful (Chen et al., 2014; 
Hou et al., 2014). GWAS studies exist at present exclusively for the effectiveness of lithium, which is 
in large part heritable according to family studies (Ewald et al., 1999; Turecki et al., 2001). These 
studies did not provide conclusive results, although they provided evidence that GRIA2, a protein of 
the AMPA glutamate receptor, plays a role in the lithium effect (Perlis et al., 2009). Genes related to 
 18 
impulsivity and suicide risk such as IMPA1 and 2, INPP1, GSK3α and β (Jimenez et al., 2013) may also 
be candidate genetic markers for the response to lithium. 
Candidate gene studies also showed that the gene XBP1, which affects cellular reactions to stress, 
may be a potential predictor of the therapeutic effect of valproic acid (Kim et al., 2009). Candidate 
genes for the prediction of the effect of lithium in bipolar patients, including the BDNF Met allele of 
rs6265 coding for an important neurotrophic factor, plays an important role in brain aging processes 
and chronification of psychiatric disorders (Salehi et al., 2013; Wang et al., 2012). Studies on the 
effect of monoaminergic antidepressants show that polymorphisms of the serotonin transporter 
gene and the gene for serotonin receptor 5HT1A have the potential to assess the antidepressant 
effect (Serretti et al., 2004; Severino et al., 2013; Zanardi et al., 2001). 
 
Epigenetics 
Each cell of our body contains an epigenetic imprint of experience in its genome. Some epigenetic 
changes can be inherited through multiple generations. The epigenetic patterning occurs at the level 
of whole chromosomes and of large chromosomal regions down to the single nucleotide level. A 
relatively well-examined epigenetic change involves the acetylation of histones leading to the local 
loosening of DNA and increased gene reading in this section. In contrast, histone methylation inhibits 
gene expression in specific gene sections. At the level of the DNA, methylation and demethylation of 
DNA inhibit and, respectively, enhance the expression of specific genes (Pena et al., 2014). 
There is preliminary evidence for epigenetic changes playing a role in the pathogenesis of bipolar 
disorders (Xiao et al., 2014). Preliminary findings suggest that the cerebral epigenetic inhibition of 
the GABAergic gene expression contribute to the development of bipolar disorders (Guidotti et al., 
2011). A typical trait of this pathology is a low expression of glutamic acid decarboxylase 67 (GAD67), 
which synthesize GABA. This results in attenuation of the inhibiting GABA system.  
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Pathogenic DNA sequences are very stable whereas epigenetic changes are reversible and therefore 
qualify for pharmacological targets. Valproic acid is a potent inhibitor of various histone deacetylases 
(HDACs). It has been showed that valproic acid specifically encourages the promoter demethylation 
of the GAD67 gene and, therefore, GAD67 expression (Dong et al., 2010). Other drugs promoting 
DNA methylation applied in bipolar disorders are clozapine and sulpiride (Dong et al., 2008). 
All of these findings suggest that epigenetic changes have a great potential to improve the 
stratification of psychiatric treatment as biomarkers. Yet the main problem is that the majority of 
epigenetic changes are specific for cells and tissues. To what extent epigenetic changes measured in 
blood cells provide information about the epigenome of the brain is currently unclear.  
 
Conclusion 
The current process of diagnosing bipolar disorders based solely on clinical symptoms has crucial 
weaknesses. Evidence for these weaknesses are low average response rates, long phases of 
treatment adjustment, and inconsistent treatment guidelines. 
Employing methods of neuropsychology, neuroradiology, immunology, genetics, and epigenetics, 
biomarkers have been proposed and evaluated. Table 2 summarizes the most promising clinical and 
biological markers to predict responses to specific treatments. To date, the most reliable markers are 
derived from psychopathology and history taking. Although there are a number of promising leads, 
no neuropsychological or biological markers have been found thus far that reliably predict individual 
therapy effectiveness. 
NIMH’s Research Domain Criteria (RDoC) (Morris and Cuthbert, 2012) provides a promising new 
research framework that takes a dimensional approach to the study of the genetic, neural and 
behavioral features of mental disorders. The domains “negative valence system” related to stress 
sensitivity and anxiety, “positive valence system” related to reward processing, and “systems for 
 20 
social processes” may be particularly important for the study of bipolar disorders. The main 
limitation of such a neuroscience-based approach to psychiatric diagnostics has been the missing link 
between clinical states and biomarkers (Fava et al., 2014). A transition from DSM to RDoC will have 
to incorporate various combinations DSM disorder categories and dimensional RDOC constructs in 
experiments (Cuthbert, 2014) . However, the high clinical utility of DSM concepts will likely be a 
major obstacle in this transition. In addition, the RDoC approach emphasizes cross-sectional 
assessment, while abnormal neurodevelopment is an important aspect in the pathogenesis of bipolar 
disorder. Identifying sensitive periods for the RDoC constructs will improve understanding of 
environmental pathogenetic components and enhance the precision of stage-related therapeutic 
interventions (Casey et al., 2014). Changing the paradigm for drug development for bipolar disorders 
based on the RDoC proposal may counteract the declining assay sensitivity of clinical trials and 
contribute to moving clinical research toward hard outcomes, such as biomarkers, and ecological 
measures of functional benefits (Vieta, 2014).    
For clinicians, it is important to completely exploit clinical markers predicting therapy effects in 
bipolar disorders, including degree of severity, type I/II classification, typical course of illness, family 
anamnesis, mixed states of manic and depressive phases, predominant polarity, degree of agitation, 
and suicidal risk (Fava et al., 2014). 
The best current predictors for treatment success are previous responses to a certain treatment and 
the evidence of an effective treatment in relatives with bipolar disorder.  
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Table 1. Predictors of bipolar spectrum disorders 
Predictor 
• Early onset of disease 
• Large number of depressive 
episodes 
• Bipolar disorders in the family history 
• Occurrence of individual maniform 
symptoms 
• Atypical depressive symptoms 
• Cyclothymic temperament 
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Table 2. Clinical and biomarkers related to treatment response in bipolar disorders  
State specifier Favorable response to References 
Mixed episode 
Agitation in manic episodes 
Severe depressive episodes 
Mild depressive episodes 
High suicidal risk 
Olanzapine, asenapine 
Asenapine, loxapine, aripiprazole 
Combination treatments 
Psychotherapy 
Lithium 
(Grunze and 
Azorin, 2014; 
Kruger et al., 
2005) 
(Brown et al., 
2013; 
Gonzalez et 
al., 2013; 
Kwentus et al., 
2012; 
McIntyre et 
al., 2009) 
(Geddes and 
Miklowitz, 
2013) 
(Kohler et al., 
2014) 
(Baldessarini 
et al., 2006) 
Course specifier   
Predominantly manic 
 
 
Predominantly depressive 
Typical manic-depressive course with 
full interepisode remission 
Seasonal affective disorder (SAD) 
Quetiapine, lithium, olanzapine, ziprasidone, 
aripiprazole, risperidone, caregiver group 
psychoeducation 
Lamotrigine, psychotherapy 
Lithium 
 
Light therapy 
(Popovic et al., 
2012; Popovic 
et al., 2013) 
 
 
(Popovic et al., 
2012; Popovic 
et al., 2013) 
(Geddes and 
Miklowitz, 
2013) 
 
(Golden et al., 
2005) 
Neuropsychological specifier   
Dependent personality traits 
High cognitive functioning 
Low cognitive functioning 
Highly structured behavioral therapy 
Cognitive behavioral therapy (CBT) 
Functional remediation 
(Grawe, 2004) 
(Geddes and 
Miklowitz, 
2013; Reinares 
et al., 2014) 
(Geddes and 
Miklowitz, 
2013; Reinares 
et al., 2014) 
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Stage of illness   
Early states 
Late states 
Psychotherapy, psychoeducation, medication 
Cognitive and functional remediation, social work 
(Reinares et 
al., 2014) 
(Reinares et 
al., 2014) 
Imaging biomarkers   
Hyperactivity in limbic brain regions 
Low activity in limbic brain regions 
White matter hyperintensity 
Gray matter volume reductions 
Antidepressants, deep brain stimulation 
Thyroid hormones (uncertain) 
Lithium 
Lithium 
(Chen et al., 
2007; 
Mayberg et 
al., 1997; 
Mayberg et 
al., 2005) 
 
(Kato et al., 
2000) 
(Chiu et al., 
2013; Moore 
et al., 2009) 
Genetic markers   
XBP1, G allele of rs2269577  
BDNF, Met allele of rs6265 
5-HTTPLR, l allele 
HTR1A, CC genotype of rs6295 
Valproic acid 
Lithium 
SSRI co-medication 
Fluvoxamine co-medication 
(Kim et al., 
2009) 
(Wang et al., 
2012) 
(Zanardi et al., 
2001) 
(Serretti et al., 
2004) 
